Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial

NCT04836260 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT04836260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04836260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial
Lead sponsor
University Hospital, Geneva
Phase
Phase 3
Overall status
Unknown status
Start date
April 8, 2021
Completion date
December 31, 2021
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, immuno-deficiency, old age; debility